ReviewCureus2024
The Role of Omega-3 Fatty Acid Supplementation in Slowing Cognitive Decline Among Elderly Patients With Alzheimer's Disease: A Systematic Review of Randomized Controlled Trials.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive function.Scientific reports · 2025Pooled it
- Food-Derived Omega-3 Fatty Acids and Cognitive Aging: Integrating Nutritional Neuroscience and Geroscience.Nutrients · 2026Review
- Review
- Dual Mechanism of Docosahexaenoic acid (DHA) in Alzheimer's Disease: PAD4 Inhibition and Autophagy Stimulation.Molecular neurobiology · 2025Article
- Review
- From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review explores the impact of omega-3 fatty acid supplementation, particularly docosahexaenoic acid (DHA), on cognitive decline in individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Omega-3 fatty acids are widely recognized for their neuroprotective properties, but the evidence regarding their efficacy in mitigating cognitive decline remains mixed. Through a comprehensive analysis of eleven randomized controlled trials, we aimed to assess the role of DHA in improving cognitive functions and slowing brain atrophy. The findings revealed that DHA supplementation demonstrated cognitive benefits, particularly in memory and hippocampal volume preservation, in some studies involving early-stage cognitive decline, while others reported negligible effects, particularly in more advanced Alzheimer's disease. The review identified variations in study design, dosage, intervention duration, and population characteristics as potential factors contributing to the inconsistencies observed across trials. Despite these mixed outcomes, DHA's safety profile and potential for early intervention in at-risk populations offer promise for its use in clinical practice. This review underscores the need for further longitudinal, large-scale studies to refine DHA dosage recommendations, optimize intervention timing, and explore personalized approaches based on genetic factors. The insights gained from this review contribute to a growing understanding of the role omega-3 fatty acids could play in managing cognitive decline and highlight future directions for research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.